- Home
- EPWK vs PHGE Comparison
EPWK vs PHGE Comparison
Compare EPWK & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPWK
- PHGE
- Stock Information
- Founded
- EPWK 2011
- PHGE 2015
- Country
- EPWK China
- PHGE Israel
- Employees
- EPWK N/A
- PHGE N/A
- Industry
- EPWK
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- EPWK
- PHGE Health Care
- Exchange
- EPWK Nasdaq
- PHGE Nasdaq
- Market Cap
- EPWK 9.5M
- PHGE 10.4M
- IPO Year
- EPWK 2025
- PHGE N/A
- Fundamental
- Price
- EPWK $0.45
- PHGE $0.54
- Analyst Decision
- EPWK
- PHGE Strong Buy
- Analyst Count
- EPWK 0
- PHGE 1
- Target Price
- EPWK N/A
- PHGE $15.00
- AVG Volume (30 Days)
- EPWK 311.2K
- PHGE 12.5M
- Earning Date
- EPWK 05-27-2025
- PHGE 08-13-2025
- Dividend Yield
- EPWK N/A
- PHGE N/A
- EPS Growth
- EPWK N/A
- PHGE N/A
- EPS
- EPWK N/A
- PHGE N/A
- Revenue
- EPWK $20,164,008.00
- PHGE N/A
- Revenue This Year
- EPWK N/A
- PHGE N/A
- Revenue Next Year
- EPWK N/A
- PHGE N/A
- P/E Ratio
- EPWK N/A
- PHGE N/A
- Revenue Growth
- EPWK 10.25
- PHGE N/A
- 52 Week Low
- EPWK $0.41
- PHGE $0.34
- 52 Week High
- EPWK $26.00
- PHGE $1.62
- Technical
- Relative Strength Index (RSI)
- EPWK N/A
- PHGE 54.55
- Support Level
- EPWK N/A
- PHGE $0.51
- Resistance Level
- EPWK N/A
- PHGE $0.55
- Average True Range (ATR)
- EPWK 0.00
- PHGE 0.08
- MACD
- EPWK 0.00
- PHGE 0.00
- Stochastic Oscillator
- EPWK 0.00
- PHGE 42.37
About EPWK EPWK Holdings Ltd. Class A Ordinary Shares
EPWK Holdings Ltd create an innovative and efficient crowdsourcing platform to connect businesses with great talents. It operates online marketplace to enable businesses (buyers) and service providers (sellers) to find each other. The platform users consist of buyers who seek talents for their jobs and sellers who offer different talents and skills. The company derives revenue mainly comes from providing various value-added services for users on both supply and demand sides.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).